Monoclonal antibodies have revolutionised therapy for autoimmune disease and cancers, but the downside is they require injection or IV infusion.

Patients prefer swallowing a pill, and because of this, doctors may delay initiation of injectable biologics, resulting in suboptimal treatment, researchers say.